Abstract
Background/Objectives People with obesity (PWO) face an increased risk of severe outcomes from COVID-19, including hospitalisation, ICU admission and death. Obesity has been seen to impair immune memory following vaccination against influenza, hepatitis B, tetanus, and rabies. Little is known regarding immune memory in PWO following COVID-19 adenovirus vector vaccination.
Subjects/Methods We investigated SARS-CoV-2 specific T cell responses in 50 subjects, five months following a two-dose primary course of ChAdOx1 nCoV-19 (AZD1222) vaccination. We further divided our cohort into PWO (n=30) and matched controls (n=20). T cell (CD4+, CD8+) cytokine responses (IFNγ, TNFα) to SARS-CoV-2 spike peptide pools were determined using multicolour flow cytometry.
Results Circulating T cells specific for SARS-CoV-2 were readily detected across our cohort, with robust responses to spike peptide stimulation across both T cell lines. PWO and controls had comparable levels of both CD4+ and CD8+ SARS-CoV-2 spike specific T cells. Polyfunctional T cells – associated with enhanced protection against viral infection – were detected at similar frequencies in both PWO and controls.
Conclusions These data indicate that PWO who have completed a primary course of ChAdOx1 COVID-19 vaccination have robust, durable, and functional antigen specific T cell immunity that is comparable to that seen in people without obesity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by the National Childrens Research Centre and a philanthropic donation from the St Vincents Foundation. Financial support for the Attune NxT was provided to Maynooth University Department of biology by Science Foundation Ireland (16/RI/3399).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Full ethical approval was granted by the St. Vincents Hospital Group Research Ethics Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint Senior Authors.
Contact Information: Dr Andrew Hogan, Email: Andrew.E.Hogan{at}mu.ie, Address: Biosciences Building, Maynooth University, Maynooth, Co. Kildare, Ireland. Phone: +35317086118
Funding: This work is supported by the National Children’s Research Centre, a philanthropic donation from the St Vincent’s Foundation. Financial support for the Attune NxT was provided to Maynooth University Department of biology by Science Foundation Ireland (16/RI/3399).
Competing interests: The authors declare no competing interests.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
